Discovery and Structure–Activity Relationship of Novel 2,3-Dihydrobenzofuran-7-carboxamide and 2,3-Dihydrobenzofuran-3(2H)-one-7-carboxamide Derivatives as Poly(ADP-ribose)polymerase-1 Inhibitors

Novel substituted 2,3-dihydrobenzofuran-7-carboxamide (DHBF-7-carboxamide) and 2,3-dihydrobenzofuran-3(2H)-one-7-carboxamide (DHBF-3-one-7-carboxamide) derivatives were synthesized and evaluated as inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). A structure-based design strategy resulted in lead compound 3 (DHBF-7-carboxamide; IC50 = 9.45 μM). To facilitate synthetically feasible derivatives, an alternative core was designed, DHBF-3-one-7-carboxamide (36, IC50 = 16.2 μM). The electrophilic 2-position of this scaffold was accessible for extended modifications. Substituted benzylidene derivatives at the 2-position were found to be the most potent, with 3′,4′-dihydroxybenzylidene 58 (IC50 = 0.531 μM) showing a 30-fold improvement in potency. Various heterocycles attached at the 4′-hydroxyl/4′-amino of the benzylidene moiety resulted in significant improvement in inhibition of PARP-1 activity (e.g., compounds 66–68, 70, 72, and 73; IC50 values from 0.718 to 0.079 μM). Compound 66 showed selective cytotoxicity in BRCA2-deficient DT40 cells. Crystal structures of three inhibitors (compounds (−)-13c, 59, and 65) bound to a multidomain PARP-1 structure were obtained, providing insights into further development of these inhibitors.

[1]  Rob W. W. Hooft,et al.  Determination of absolute structure using Bayesian statistics on Bijvoet differences , 2008, Journal of applied crystallography.

[2]  J. Pascal,et al.  Structural Basis for DNA Damage–Dependent Poly(ADP-ribosyl)ation by Human PARP-1 , 2012, Science.

[3]  A. Lau,et al.  4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. , 2008, Journal of medicinal chemistry.

[4]  V. I. Rozenberg,et al.  An improved synthesis of (S)-(+)- and (R)-(−)-[2.2]paracyclophane-4-carboxylic acid , 1998 .

[5]  H. Flack,et al.  On enantiomorph‐polarity estimation , 1983 .

[6]  G N Murshudov,et al.  Use of TLS parameters to model anisotropic displacements in macromolecular refinement. , 2001, Acta crystallographica. Section D, Biological crystallography.

[7]  W. Kraus,et al.  On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. , 2012, Genes & development.

[8]  Bernhard Lüscher,et al.  Toward a unified nomenclature for mammalian ADP-ribosyltransferases. , 2010, Trends in biochemical sciences.

[9]  R. Armen,et al.  Structural Implications for Selective Targeting of PARPs , 2013, Front. Oncol..

[10]  H. Meshram,et al.  Zirconium(IV) Chloride Catalyzed Cyclization of ortho‐Allylphenols: Synthesis of 2‐Methyl‐2,3‐dihydrobenzofurans , 2004 .

[11]  G. Poirier,et al.  Poly(ADP-ribose) degradation by post-nuclear extracts from human cells. , 2002, Biochimie.

[12]  Jung-Sik Kim,et al.  Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors , 2009, EMBO molecular medicine.

[13]  C. Toniatti,et al.  Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. , 2009, Journal of medicinal chemistry.

[14]  D. Ferraris,et al.  Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. , 2010, Journal of medicinal chemistry.

[15]  M. Hixon,et al.  Discovery of novel benzo[b][1,4]oxazin-3(4H)-ones as poly(ADP-ribose)polymerase inhibitors. , 2013, Bioorganic & medicinal chemistry letters.

[16]  Maulik R. Patel,et al.  Design and Synthesis of N‐Substituted Indazole‐3‐Carboxamides as Poly(ADP‐ribose)polymerase‐1 (PARP‐1) Inhibitors † , 2012, Chemical biology & drug design.

[17]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[18]  S. Gmouh,et al.  Onium salt supported organic synthesis in water: application to Grieco's multicomponent reaction , 2008 .

[19]  S. Rohani,et al.  Chiral discrimination in diastereomeric salts of chlorine-substituted mandelic acid and phenylethylamine. , 2010, Chirality.

[20]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[21]  Eric F. Johnson,et al.  ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models , 2007, Clinical Cancer Research.

[22]  S. Kaufmann,et al.  PARP inhibition: PARP1 and beyond , 2010, Nature Reviews Cancer.

[23]  T. Gilmore,et al.  Nonsteroidal dissociated glucocorticoid agonists containing azaindoles as steroid A-ring mimetics. , 2010, Journal of medicinal chemistry.

[24]  Y. Pommier,et al.  Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. , 2012, Cancer research.

[25]  N. Curtin,et al.  Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial , 2007, Molecular Cancer Therapeutics.

[26]  W. Kraus,et al.  Regulation of chromatin structure and chromatin-dependent transcription by poly(ADP-ribose) polymerase-1: possible targets for drug-based therapies. , 2007, Sub-cellular biochemistry.

[27]  J. Pascal,et al.  Purification of human PARP-1 and PARP-1 domains from Escherichia coli for structural and biochemical analysis. , 2011, Methods in molecular biology.

[28]  T. Le,et al.  In silico identification of poly(ADP-ribose)polymerase-1 inhibitors and their chemosensitizing effects against cisplatin-resistant human gastric cancer cells. , 2013, Bioorganic & medicinal chemistry letters.

[29]  Jie Zhang,et al.  Design and synthesis of poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors. Part 3: In vitro evaluation of 1,3,4,5-tetrahydro-benzo[c][1,6]- and [c][1,7]-naphthyridin-6-ones. , 2003, Bioorganic & medicinal chemistry letters.

[30]  N. Curtin,et al.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. , 2013, Molecular aspects of medicine.

[31]  Y. Pommier,et al.  Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib , 2013, Molecular Cancer Therapeutics.

[32]  Graeme Winter,et al.  xia2: an expert system for macromolecular crystallography data reduction , 2010 .

[33]  Jamin D Steffen,et al.  Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer. , 2014, Cancer research.

[34]  N. Suzuki,et al.  Synthesis and Structure‐Activity Relationship of 4‐Substituted Benzoic Acids and their Inhibitory Effect on the Biosynthesis of Fatty Acids and Sterols , 2005, Archiv der Pharmazie.

[35]  Eric F. Johnson,et al.  Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. , 2009, Journal of medicinal chemistry.

[36]  Eric F. Johnson,et al.  Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer. , 2008, Bioorganic & medicinal chemistry.

[37]  R. Gabel,et al.  Nucleophilic annulations of aromatics. Novel route to benzo-fused ring systems via oxazoline activation , 1981 .

[38]  Samuel H. Wilson,et al.  In situ analysis of repair processes for oxidative DNA damage in mammalian cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[39]  E. Casale,et al.  PARP inhibitors in cancer therapy: an update , 2013, Expert opinion on therapeutic patents.

[40]  T. Talele,et al.  Synthesis and SAR optimization of quinazolin-4(3H)-ones as poly(ADP-ribose)polymerase-1 inhibitors. , 2012, European journal of medicinal chemistry.

[41]  Aneesa,et al.  Synthesis and antimicrobial activity of novel analogs of trifenagrel , 2009 .

[42]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[43]  T. Högberg,et al.  Potential antipsychotic agents. 7. Synthesis and antidopaminergic properties of the atypical highly potent (S)-5-bromo-2,3-dimethoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide and related compounds. A comparative study. , 1990, Journal of medicinal chemistry.

[44]  Mitsuko Masutani,et al.  A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. , 2003, Nucleic acids research.

[45]  A. Bürkle,et al.  How to Kill Tumor Cells with Inhibitors of Poly(adp-ribosyl)ation the Role of Poly(adp-rlbosyl)ation in Carcinogenesis , 2022 .

[46]  Vijay T. Ahuja,et al.  In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists. , 2009, Journal of medicinal chemistry.

[47]  M. Faramarzi,et al.  Synthesis, antibacterial activity, and quantitative structure-activity relationships of new (Z)-2-(nitroimidazolylmethylene)-3(2H)-benzofuranone derivatives. , 2007, Bioorganic & medicinal chemistry letters.

[48]  J. Weigelt,et al.  Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors , 2012, Nature Biotechnology.

[49]  M. Toulmonde,et al.  A review of PARP inhibitors: from bench to bedside. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  A. Tomkinson,et al.  Translocation of XRCC1 and DNA ligase IIIα from centrosomes to chromosomes in response to DNA damage in mitotic human cells , 2005, Nucleic acids research.

[51]  Martin Zacharias,et al.  A family of macrodomain proteins reverses cellular mono-ADP-ribosylation , 2013, Nature Structural &Molecular Biology.

[52]  Murray S. Cohen,et al.  Hydrazine Derivatives. I. Benzalthio- and Bisbenzaldithio-Salicylhydrazides , 1953 .

[53]  G. R. Srinivasa,et al.  Palladium-catalyzed simple and efficient hydrogenative cleavage of azo compounds using recyclable polymer-supported formate , 2005 .

[54]  W. Kraus,et al.  New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs , 2012, Nature Reviews Molecular Cell Biology.

[55]  T. Katsuki,et al.  Catalytic asymmetric epoxidation of unfunctionalized olefins using chiral (salen)manganese(III) complexes , 1991 .

[56]  R. Varma,et al.  Alumina-mediated condensation. A simple synthesis of aurones , 1992 .

[57]  J. Doroshow,et al.  Advances in using PARP inhibitors to treat cancer , 2012, BMC Medicine.

[58]  Yves Pommier,et al.  Differential and Common DNA Repair Pathways for Topoisomerase I- and II-Targeted Drugs in a Genetic DT40 Repair Cell Screen Panel , 2013, Molecular Cancer Therapeutics.

[59]  C. Toniatti,et al.  Synthesis and biological evaluation of substituted 2-phenyl-2H-indazole-7-carboxamides as potent poly(ADP-ribose) polymerase (PARP) inhibitors. , 2010, Bioorganic & medicinal chemistry letters.